{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-006746","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2022-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.868143+00:00","generated_at":"2026-06-27T18:57:45.515214+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroPace reports preliminary Q4 2021 revenue of $11.0M (+2% YoY); FY2021 $45.2M (+10% YoY)","bullets":["Q4 2021 revenue ~$11.0M (+2% YoY); initial implant $8.5M (+10%), replacement $2.5M (-19%).","FY2021 revenue ~$45.2M (+10% YoY); initial implant $33.7M (+20%), replacement $11.5M (-12%).","150 centers performed RNS implant in 2021, up 14% from 132 centers in 2020.","Enrolled first patient in adolescent study to expand indications beyond current pool.","Full Q4 and FY results expected in mid-March 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-006746","json":"https://secwatch.observer/filing/0001193125-22-006746.json","markdown":"https://secwatch.observer/filing/0001193125-22-006746.md","text":"https://secwatch.observer/filing/0001193125-22-006746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000119312522006746/0001193125-22-006746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000119312522006746/d276070d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:57:45.515214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}